Your cart is empty
Start Shopping
Starting at $37
Independently tested by Novagen Analytical Labs
Verify this batch with the lab View the certificate
Every batch we sell carries its own verification key. This one is NGL-2026-6ZKG17. Enter it on the laboratory's own website and it returns the certificate for this exact batch. That page belongs to the lab, not to us.
Tesamorelin is a synthetic growth hormone-releasing hormone (GHRH) analogue peptide designed to stimulate the natural release of growth hormone (GH) from the pituitary gland. By mimicking the action of endogenous GHRH, Tesamorelin promotes GH secretion in a physiological pattern, supporting research into metabolism, muscle growth, and fat regulation.
This peptide is a stable, high-purity formulation ideal for scientific and laboratory research. Unlike direct HGH injections, Tesamorelin works indirectly encouraging the body’s own GH production rhythm rather than suppressing it.
This order qualifies for free US shipping.
This material is sold for laboratory research use only. Terms of sale apply. Not for human consumption, nor medical, veterinary, or household uses. Please familiarize yourself with our Terms & Conditions prior to ordering.

| Title | Range | Discount |
|---|---|---|
| Volume pricing - 10% at 5+, 20% at 10+ | 5 - 9 | 10% |
| Volume pricing - 10% at 5+, 20% at 10+ | 10 + | 20% |
| Molecular Formula | C₂₂₁H₃₆₆N₇₂O₆₇S |
| CAS Number | 218949-48-5 |
| Molar Mass | 5135.86 g/mol |
| Amino Acid Sequence | Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) |
| PubChem CID | 146681838 |
| Primary Research Area |
Reduce Visceral Adipose Tissue (VAT) in HIV-infected patients with lipodystrophy Insulin Resistance Obesity Nonalcoholic Fatty Liver Disease (NAFLD) GHRH Receptor Agonist Stimulate GH/IGF-1 Improve Metabolic Profile Improve Fat Quality |
| Purity | ≥98% |
| Research Summary | Description |
|---|---|
| Tesamorelin improves fat quality independent of changes in fat quantity |
Summary: A notable finding is Tesamorelin's ability to improve ""fat quality"" independently of changes in fat quantity. Stanley et al. (2021) demonstrated that Tesamorelin increased both visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT) density in people living with HIV (PLWH). Citation: Stanley, T. L., Stanley, A. N., Stanley, T. L., & Grinspoon, S. K. (2021). Tesamorelin Improves Fat Quality Independent of Changes in Fat Quantity. Journal of Acquired Immune Deficiency Syndromes, 87(2), e213. |
| The growth hormone releasing hormone analogue, Tesamorelin, decreases muscle fat and increases muscle area in adults with HIV |
Summary: This exploratory secondary analysis of two clinical trials investigated the effects of tesamorelin on skeletal muscle fat and area in people living with HIV (PLWH) with abdominal obesity. The study found that tesamorelin significantly increased the density (less fat) and area of several truncal muscle groups in responders (those who experienced a significant decrease in visceral adipose tissue). Citation: Adrian, S., Scherzinger, A., Sanyal, A., & Grinspoon, S. K. (2019). The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV. BMC Medicine, 17(1), 173. |
| Effects of Tesamorelin on nonalcoholic fatty liver disease in HIV: A randomized, double-blind, multicenter trial |
Summary: This randomized, double-blind, placebo-controlled trial investigated the effects of tesamorelin on nonalcoholic fatty liver disease (NAFLD) in people living with HIV (PLWH). The study found that tesamorelin significantly reduced hepatic fat fraction (HFF) compared to placebo after 12 months, suggesting a beneficial effect on liver fat. Glucose parameters did not significantly differ between groups. Citation: Stanley, T. L., Fourman, L. T., Feldpausch, M. N., Purdy, J., Aepfelbacher, J., Kellogg, A., ... & Grinspoon, S. K. (2020). Effects of Tesamorelin on Nonalcoholic Fatty Liver Disease in HIV: A Randomized, Double-Blind, Multicenter Trial. Gastroenterology, 158(1), 132–142.e5. |
Summary: A notable finding is Tesamorelin's ability to improve ""fat quality"" independently of changes in fat quantity. Stanley et al. (2021) demonstrated that Tesamorelin increased both visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT) density in people living with HIV (PLWH).
Citation: Stanley, T. L., Stanley, A. N., Stanley, T. L., & Grinspoon, S. K. (2021). Tesamorelin Improves Fat Quality Independent of Changes in Fat Quantity. Journal of Acquired Immune Deficiency Syndromes, 87(2), e213.
Summary: This exploratory secondary analysis of two clinical trials investigated the effects of tesamorelin on skeletal muscle fat and area in people living with HIV (PLWH) with abdominal obesity. The study found that tesamorelin significantly increased the density (less fat) and area of several truncal muscle groups in responders (those who experienced a significant decrease in visceral adipose tissue).
Citation: Adrian, S., Scherzinger, A., Sanyal, A., & Grinspoon, S. K. (2019). The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV. BMC Medicine, 17(1), 173.
Summary: This randomized, double-blind, placebo-controlled trial investigated the effects of tesamorelin on nonalcoholic fatty liver disease (NAFLD) in people living with HIV (PLWH). The study found that tesamorelin significantly reduced hepatic fat fraction (HFF) compared to placebo after 12 months, suggesting a beneficial effect on liver fat. Glucose parameters did not significantly differ between groups.
Citation: Stanley, T. L., Fourman, L. T., Feldpausch, M. N., Purdy, J., Aepfelbacher, J., Kellogg, A., ... & Grinspoon, S. K. (2020). Effects of Tesamorelin on Nonalcoholic Fatty Liver Disease in HIV: A Randomized, Double-Blind, Multicenter Trial. Gastroenterology, 158(1), 132–142.e5.
Your cart is empty
Start Shopping